Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Deszk – page 25

383 clinical trials in Deszk, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Deszk at a glance
383
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

383 trials in Deszk

Open in trial search

Study of AB-1002 gene therapy given through coronary arteries in adults with severe (NYHA Class III) heart failure caused by non-ischemic cardiomyopathy

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:AB-1002
  • Sponsor:Askbio Inc.

Study of iptacopan effectiveness in achieving remission in patients with active ANCA-associated vasculitis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Study on Elamipretide for Patients with Dry Age-Related Macular Degeneration (Dry AMD)

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Elamipretide Trihydrochloride
  • Sponsor:Stealth Biotherapeutics Inc.

Study Comparing Bomedemstat and Hydroxycarbamide for Patients with Essential Thrombocythemia

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Bomedemstat
  • Sponsor:Merck Sharp & Dohme LLC

Myelofibrosis+1

Not recruiting

Study of Navtemadlin for Patients with Myelofibrosis Resistant to JAK Inhibitors

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Danazol
  • Sponsor:Kartos Therapeutics Inc.

Study on the Effects of AZD5004 and Semaglutide for Adults with Type 2 Diabetes

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:Astrazeneca AB

Cardiac failure acute

Not recruiting

Study of dapagliflozin effects in patients hospitalized with acute heart failure

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin Propanediol Monohydrate
  • Sponsor:The Brigham And Women’s Hospital Inc.

Chronic hepatitis B

Not recruiting

Study on Bepirovirsen for Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogue Treatment

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Bepirovirsen
  • Sponsor:Glaxosmithkline Research & Development Limited

Study on Durvalumab and Domvanalimab for Patients with Stage III Unresectable Non-Small Cell Lung Cancer After Chemoradiation Therapy

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Domvanalimab
  • Sponsor:Astrazeneca AB

Crohn's disease

Not recruiting

Study on the Effects of Ozanimod for Children with Moderate to Severe Crohn's Disease Not Responding to Usual Treatments

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:0–17 years
  • Substances:Ozanimod
  • Sponsor:Celgene International II S.a.r.l.

Bladder cancer

Not recruiting

Study of Pembrolizumab and Enfortumab Vedotin with Surgery vs. Surgery Alone for Patients with Muscle-Invasive Bladder Cancer Who Cannot or Choose Not to Use Cisplatin

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Merck Sharp & Dohme LLC

Study on Preventing Infections After Abdominal Surgery Using D-PLEX with Doxycycline Hyclate for Patients Undergoing Abdominal Surgery

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Doxycycline Hyclate
  • Sponsor:Polypid Ltd.

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Deszk

What the registry says about research in the country

01 Lung Cancer Research

Innovative clinical trials focusing on non-small cell lung cancer (NSCLC) treatments, particularly targeting advanced and unresectable cases.

  • Advanced Non-Squamous NSCLC with HER2 Mutations
  • Stage III Unresectable NSCLC
  • Combination Therapy Approaches

Studies evaluating novel therapeutic agents including zongertinib and combination treatments with durvalumab plus domvanalimab to improve patient outcomes.

02 Targeted Therapies

Research examining personalized treatment approaches for patients with specific genetic markers and protein expressions.

  • HER2 Mutation-Targeted Treatments
  • PD-L1 Expression Analysis
  • Immunotherapy Combinations

Investigations comparing new targeted therapies against standard-of-care treatments for better progression-free survival.

03 Treatment Innovation

Advancement in therapeutic strategies for locally advanced lung cancer patients.

  • Chemoradiation Therapy
  • Novel Drug Combinations
  • Biomarker-Driven Research

Focus on developing improved treatment options for patients with unresectable stage III NSCLC following concurrent chemoradiation.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.